Akesis: Chromium/sulfonylurea combo benefits diabetics

By Elaine Rigoli

Tampa, Fla., Aug. 21 - Akesis Pharmaceuticals, Inc. said Monday that a study published in the August issue of Diabetes Care demonstrates the positive clinical effects of the trace element chromium when combined with a commonly prescribed oral antidiabetic drug.

The study, a randomized, double-blind, placebo-controlled trial conducted by researchers at Pennington Biomedical Research Center in Baton Rouge, La., concludes that the addition of chromium to a regimen consisting of a sulfonylurea drug in subjects with type 2 diabetes significantly improves insulin sensitivity, improves glucose control and attenuates body weight gain.

Akesis said it is developing proprietary products designed to lower and control blood glucose levels in patients with type 2 diabetes and holds numerous issued patents and patent applications relating to the use of chromium, vanadium and other components with sulfonylureas and other classes of diabetic agents.

"Akesis looks forward to taking steps to confirm the clinical utility of its proprietary products in future company-sponsored studies," president and chief executive officer Edward B. Wilson said in a news release.

Akesis is a pharmaceutical company based in San Diego.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.